Atacicept

Protein / enzyme therapeutic

Acceleratedapproval

Evidence outlook

Accelerated approval: IgA Nephropathy (label: To reduce proteinuria in adults with primary IgAN at risk for disease progression)

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Company guidance: data expected fourth quarter of 2026 (Vera Therapeutics, Inc., 5 Nov 2026). “In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or anti-nephrin autoantibodies.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
IgA Nephropathy
Other / comorbidity
NCT05609812 · Vera Therapeutics, Inc.
2022-11-02 – 2028-12-15 · Lupus Nephritis (LN)
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT00624338 · EMD Serono
2008-01 – 2012-10 · Lupus Erythematosus, Systemic
What this study did
NCT00573157 · EMD Serono
2007-12 – 2009-04 · Lupus Nephritis
What this study did
Phase 2 (13)
IgA Nephropathy
NCT06674577 · Vera Therapeutics, Inc.
2024-12-01 – 2031-05-21 · IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
What this study did
NCT07020923 · Vera Therapeutics, Inc.
2025-05-29 – 2027-09 · IgA Nephropathy (IgAN), Berger Disease
What this study did
NCT02808429 · EMD Serono Research & Development Institute, Inc.
2017-01-31 – 2020-02-07 · IgA Nephropathy
What this study did
Other / comorbidity
NCT06983028 · Vera Therapeutics, Inc.
2025-07-07 – 2027-11 · pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
What this study did
NCT02070978 · EMD Serono
2014-07-29 – 2018-02-09 · Lupus Erythematosus, Systemic
What this study did
NCT01972568 · EMD Serono
2013-12 – 2016-09 · Lupus Erythematosus, Systemic
What this study did
NCT01440231 · EMD Serono
2012-02 – 2014-02 · Systemic Lupus Erythematosus
What this study did
NCT00853762 · EMD Serono
2009-03 – 2011-02 · Relapsing Multiple Sclerosis
What this study did
NCT00624468 · EMD Serono
2008-06 – 2011-01 · Optic Neuritis
What this study did
NCT00664521 · Merck KGaA, Darmstadt, Germany
2008-03 – 2010-10 · Rheumatoid Arthritis
What this study did
NCT00595413 · EMD Serono
2007-09 – 2009-10 · Rheumatoid Arthritis
What this study did
NCT00642902 · EMD Serono
2008-04 – 2009-09 · Relapsing Multiple Sclerosis
What this study did
NCT00430495 · EMD Serono
2006-12 – 2009-09 · Rheumatoid Arthritis
What this study did
Phase 1 (1)
Other / comorbidity
NCT01369628 · EMD Serono
2011-06 – 2011-11 · Lupus Nephritis
What this study did

Competitive landscape

This drug's own stage for IgA Nephropathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Atacicept: this drugApprovedProtein / enzyme therapeuticBLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Partial signalFeatured results are non-efficacy only in this race
Atrasentan (Vanrafia)ApprovedSmall moleculeEndothelin A receptorPartial signal
NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001
Budesonide (targeted-Release) (TARPEYO / Nefecon)ApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing.
Sparsentan (Filspari)ApprovedSmall moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Partial signalFeatured results are non-efficacy only in this race
FelzartamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
JADE101Phase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
SefaxersenPhase 3RNA / oligonucleotideComplement factor B (CFB)Partial signal
NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ARO-CFBPhase 1RNA / oligonucleotideComplement factor B (CFB) mRNAnot yet gradedNo reviewed efficacy summary in this indication
Opemalirsen
Phase 1(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Atacicept to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Phase 2pMN, IgAN, Nephrotic Syndrome, MCD, FSGSRecruiting
Est. primary completion 2027-11 · NCT06983028 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 2IgA NephropathyEnrolling by invitation
Est. primary completion 2031-05-21 · NCT06674577 · CT.gov ↗
What to watch

See the full readout calendar ↗